Intrinsiqq
Zentalis Pharmaceuticals, Inc. logo

Zentalis Pharmaceuticals, Inc.

ZNTL

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$134M
EPS-$1.93
P/E-0.70
P/FCF-1.00
EV/EBITDA0.39
FCF Yield–
Div. Yield–
Net Debt/FCF1.4x
Zentalis Pharmaceuticals, Inc. intrinsic value
52-Week Range
$1.33$4.06

Profitability & Returns

Revenue (FY)

$0.00

▼ -100.0% YoY

Net Income (TTM)

-$142M

▲ +17.4% YoY

Op. Margin

–

ROIC

-52.94%

▼ -3.0pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$134M

▲ +26.8% YoY

Op. Cash Flow (TTM)

-$134M

▲ +26.7% YoY

Net Debt

-$192M

Net Cash Position

Cash & Equiv.

$229M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with ZNTL

CompareIntrinsic value
ABCLAbCellera Biologics Inc.
$9.69-7.45%16
DERMJourney Medical Corp
$3.32-6.48%15
FBIOFortress Biotech Inc.
$1.90+7.34%59
RMTIRockwell Medical, Inc.
$5.82-7.03%34
LITSLite Strategy, Inc.
$0.80-4.45%25
ENTAEnanta Pharmaceuticals Inc.
$7.62-4.51%25
WVEWave Life Sciences Ltd.
$2.56-5.88%40
OMEROmeros Corporation
$13.21-5.71%28

Held by ETFs

ZNTL is in 5 US ETFs. The largest of them, with ZNTL's weight in each:

Zentalis Pharmaceuticals (ZNTL) in three numbers

Quality score
10/100
Best check: net debt, -$192M. Weakest: return on capital, -52.9%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-0.70
Negative: a loss over the last twelve months. Price to free cash flow -1.00.
Financials

Questions about Zentalis Pharmaceuticals

Is Zentalis Pharmaceuticals a high-quality business?

Zentalis Pharmaceuticals scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$192M, and its weakest is return on capital at -52.9%. The Quality tab shows every check against its target.

Does Zentalis Pharmaceuticals (ZNTL) pay a dividend?

No. Zentalis Pharmaceuticals (ZNTL) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 7.5% buyback yield. The Dividends tab shows its cash returns.

Source: 10-Q filed 4 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in ZNTL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ZNTL

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.